
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.6145 | -10.5051713822 | 5.8495 | 6.09 | 5.2 | 2756964 | 5.67222527 | CS |
4 | -1.28 | -19.6469685342 | 6.515 | 7.1 | 5.2 | 2554062 | 6.15502381 | CS |
12 | -3.595 | -40.7134767837 | 8.83 | 8.85 | 5.2 | 2382579 | 6.82676697 | CS |
26 | -1.685 | -24.3497109827 | 6.92 | 11.16 | 5.2 | 2690492 | 7.54230983 | CS |
52 | -5.065 | -49.1747572816 | 10.3 | 11.5 | 5.2 | 2998033 | 7.52842905 | CS |
156 | -2.285 | -30.3856382979 | 7.52 | 23.49 | 2.09 | 3031998 | 8.05841545 | CS |
260 | 2.135 | 68.8709677419 | 3.1 | 35.1 | 2.09 | 2569275 | 9.79573806 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions